FTC Backs Single 30-Month Stay On Generic Approvals In Patent Litigation
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation
You may also be interested in...
FDA Questions First-To-File Exclusivity As Generic Reforms Pass Senate
FDA has reservations about the current first-to-file basis for 180-day exclusivity, FDA Chief Counsel Daniel Troy acknowledged at a June 17 Senate Judiciary Committee hearing on generic drug reforms
FDA Questions First-To-File Exclusivity As Generic Reforms Pass Senate
FDA has reservations about the current first-to-file basis for 180-day exclusivity, FDA Chief Counsel Daniel Troy acknowledged at a June 17 Senate Judiciary Committee hearing on generic drug reforms
FDA Questions First-To-File Exclusivity As Generic Reforms Pass Senate
FDA has reservations about the current first-to-file basis for 180-day exclusivity, FDA Chief Counsel Daniel Troy acknowledged at a June 17 Senate Judiciary Committee hearing on generic drug reforms